A Phase 1b, Master Protocol Evaluating the Safety, Tolerability, Pharmacokinetics, and Efficacy of AMG 510 in Subjects With Advanced Solid Tumors With KRAS p.G12C Mutation
Sponsor: |
Amgen |
Enrolling: |
Male and Female Patients |
IRB Number: |
AAAS7409 |
U.S. Govt. ID: |
NCT04185883 |
Contact: |
Research Nurse Navigator: 212-342-5162 / cancerclinicaltrials@cumc.columbia.edu |
This study is being done to obtain information on the safety and side effects, good or bad, of two new drug combinations; AMG 510 plus trametinib and AMG 510 plus AMG 404. Subjects will participate in one of two research groups. Group A will receive AMG 510 and trametinib. Research Group B will receive AMG 510 and AMG 404. AMG 510 is an anticancer drug that is being developed for tumors with a specific mutation called KRAS p.G12C. AMG 404 is an anticancer drug that works by activating an immune response against the cancer by blocking the activity of a molecule called PD-1. Trametinib is an anticancer drug that interferes with the growth and spread of cancer cells in the body.
Investigator
Benjamin Herzberg, MD
Are you at least 18 years old? |
Yes |
No |
Do you have confirmed locally-advanced or metastatic malignancy? |
Yes |
No |
Are you able to take oral medications? |
Yes |
No |
Are you willing to record your daily intake of the study drugs? |
Yes |
No |